OBJECTIVE: To prospectively evaluate the clinical course of patients with severe aortic stenosis (AS) and identify factors associated with treatment selection and patient outcome. METHODS: Patients diagnosed with severe AS in the Rotterdam area were included between June 2006 and May 2009. Patient characteristics, echocardiogram, brain natriuretic peptide (NT-proBNP), and treatment strategy were assessed at baseline, and after 6, 12, and 24 months. Endpoints were aortic valve replacement (AVR) / transcatheter aortic valve implantation (TAVI) and death. RESULTS: The study population comprised 191 patients, 132 were symptomatic and 59 asymptomatic at study entry. Two-year cumulative survival of symptomatic patients was 89.8 % (95 % CI 79.8-95.0 %) after AVR/TAVI and 72.6 % (95 % CI 59.7-82.0 %) with conservative treatment. Two-year cumulative survival of asymptomatic patients was 91.5 % (95 % CI 80.8-96.4 %). Two-year cumulative incidence of AVR/TAVI was 55.9 % (95 % CI 47.5-63.5 %) in symptomatic patients. Sixty-eight percent of asymptomatic patients developed symptoms, median time to symptoms was 13 months; AVR/TAVI cumulative incidence was 38.3 % (95 % CI 23.1-53.3 %). Elderly symptomatic patients with multiple comorbidities were more likely to receive conservative treatment. CONCLUSIONS: In contemporary Dutch practice many symptomatic patients do not receive invasive treatment of severe AS. Two-thirds of asymptomatic patients develop symptoms within 2 years, illustrating the progressive nature of severe AS. Treatment optimisation may be achieved through careful individualised assessment in a multidisciplinary setting.
OBJECTIVE: To prospectively evaluate the clinical course of patients with severe aortic stenosis (AS) and identify factors associated with treatment selection and patient outcome. METHODS:Patients diagnosed with severe AS in the Rotterdam area were included between June 2006 and May 2009. Patient characteristics, echocardiogram, brain natriuretic peptide (NT-proBNP), and treatment strategy were assessed at baseline, and after 6, 12, and 24 months. Endpoints were aortic valve replacement (AVR) / transcatheter aortic valve implantation (TAVI) and death. RESULTS: The study population comprised 191 patients, 132 were symptomatic and 59 asymptomatic at study entry. Two-year cumulative survival of symptomatic patients was 89.8 % (95 % CI 79.8-95.0 %) after AVR/TAVI and 72.6 % (95 % CI 59.7-82.0 %) with conservative treatment. Two-year cumulative survival of asymptomatic patients was 91.5 % (95 % CI 80.8-96.4 %). Two-year cumulative incidence of AVR/TAVI was 55.9 % (95 % CI 47.5-63.5 %) in symptomatic patients. Sixty-eight percent of asymptomatic patients developed symptoms, median time to symptoms was 13 months; AVR/TAVI cumulative incidence was 38.3 % (95 % CI 23.1-53.3 %). Elderly symptomatic patients with multiple comorbidities were more likely to receive conservative treatment. CONCLUSIONS: In contemporary Dutch practice many symptomatic patients do not receive invasive treatment of severe AS. Two-thirds of asymptomatic patients develop symptoms within 2 years, illustrating the progressive nature of severe AS. Treatment optimisation may be achieved through careful individualised assessment in a multidisciplinary setting.
Authors: Martin B Leon; Craig R Smith; Michael Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; David L Brown; Peter C Block; Robert A Guyton; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Pamela S Douglas; John L Petersen; Jodi J Akin; William N Anderson; Duolao Wang; Stuart Pocock Journal: N Engl J Med Date: 2010-09-22 Impact factor: 91.245
Authors: Stuart J Head; Ad J J C Bogers; Patrick W Serruys; Johanna J M Takkenberg; A Pieter Kappetein Journal: Lancet Date: 2011-05-28 Impact factor: 79.321
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Samuel V Lichtenstein; Anson Cheung; Jian Ye; Christopher R Thompson; Ronald G Carere; Sanjeevan Pasupati; John G Webb Journal: Circulation Date: 2006-07-31 Impact factor: 29.690
Authors: Vuyisile T Nkomo; Julius M Gardin; Thomas N Skelton; John S Gottdiener; Christopher G Scott; Maurice Enriquez-Sarano Journal: Lancet Date: 2006-09-16 Impact factor: 79.321
Authors: Thomas N Robinson; Ben Eiseman; Jeffrey I Wallace; Skotti D Church; Kim K McFann; Shirley M Pfister; Terra J Sharp; Marc Moss Journal: Ann Surg Date: 2009-09 Impact factor: 12.969
Authors: Martijn W A van Geldorp; Menno van Gameren; Arie Pieter Kappetein; Bardia Arabkhani; Lotte E de Groot-de Laat; Johanna J M Takkenberg; Ad J J C Bogers Journal: Eur J Cardiothorac Surg Date: 2009-03-20 Impact factor: 4.191
Authors: M W A van Geldorp; H J Heuvelman; A P Kappetein; J J V Busschbach; J J M Takkenberg; A J J C Bogers Journal: Neth Heart J Date: 2013-01 Impact factor: 2.380
Authors: Vasiliki Tsampasian; Ciaran Grafton-Clarke; Abraham Edgar Gracia Ramos; George Asimakopoulos; Pankaj Garg; Sanjay Prasad; Liam Ring; Gerry P McCann; James Rudd; Marc R Dweck; Vassilios S Vassiliou Journal: Open Heart Date: 2022-05
Authors: M W A van Geldorp; H J Heuvelman; A P Kappetein; J J V Busschbach; D J Cohen; J J M Takkenberg; A J J C Bogers Journal: Neth Heart J Date: 2013-01 Impact factor: 2.380
Authors: Richard P Steeds; Matthias Lutz; Jeetendra Thambyrajah; Antonio Serra; Eberhard Schulz; Jiri Maly; Marco Aiello; Tanja K Rudolph; Guy Lloyd; Alessandro Santo Bortone; Karl Eugen Hauptmann; Alberto Clerici; Georg Delle-Karth; Johannes Rieber; Ciro Indolfi; Massimo Mancone; Loic Belle; Alexander Lauten; Martin Arnold; Berto J Bouma; Cornelia Deutsch; Jana Kurucova; Martin Thoenes; Peter Bramlage; Norbert Frey; David Messika-Zeitoun Journal: J Am Heart Assoc Date: 2019-09-24 Impact factor: 5.501
Authors: Mevlüt Çelik; Milan Milojevic; Andras P Durko; Frans B S Oei; Edris A F Mahtab; Ad J J C Bogers Journal: J Cardiovasc Dev Dis Date: 2021-03-31